A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age

Pneumococcal disease can be serious and debilitating in older adults. Pneumococcal conjugate vaccines (PCVs), such as the 13-valent PCV (PCV13), reduce pneumococcal disease rates caused by vaccine serotypes. Development of PCVs offering additional coverage against serotypes not contained in PCV13 ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Essink, Brandon, Peterson, James, Yacisin, Kari, Lal, Himal, Mirza, Sarah, Xu, Xia, Scully, Ingrid L., Scott, Daniel A., Gruber, William C., Jansen, Kathrin U., Watson, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475590/
https://www.ncbi.nlm.nih.gov/pubmed/33661716
http://dx.doi.org/10.1080/21645515.2021.1890511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475590/
https://www.ncbi.nlm.nih.gov/pubmed/33661716
http://dx.doi.org/10.1080/21645515.2021.1890511

Ejemplares similares